Name | (2-decoxy-3-dodecylsulfanylpropyl) [(2R,3S,5R)-3-fluoro-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl hydrogen phosphate |
---|---|
Synonyms |
Fosalvudine tidoxil
Fosalvudine HDP 99.0003 |
Description | Fosalvudine tidoxil is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Fosalvudine tidoxil is a prodrug derived from Alovudine (HY-B1516). Fosalvudine tidoxil is less toxic than Alovudine and can be used for the research of HIV-1 infection[1]. |
---|---|
Related Catalog | |
Target |
Nucleoside reverse transcriptase[1] |
In Vivo | Fosalvudine tidoxil (15-100 mg/kg/day; oral; 8 weeks) 对大鼠产生显著的线粒体肝毒性[1]。 Animal Model: Sprague-Dawley rats[1] Dosage: 15, 40, or 100 mg/kg/day Administration: Oral gavage, 8 weeks Result: Induced significant mtDNA depletion. At doses of 15, 40, and 100 mg/kg, the mean hepatic mtDNA values were 62, 64, and 47% of control values, respectively. |
References |
Molecular Formula | C35H64FN2O8PS |
---|---|
Molecular Weight | 722.93 |
Exact Mass | 722.41100 |
PSA | 164.19000 |
LogP | 8.78420 |